SHAREHOLDER ALERT: Weiss Law Investigates Vallon Pharmaceuticals, Inc.

NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Vallon Pharmaceuticals, Inc. ("Vallon" or the "Company") (NASDAQ:VLON), in connection with the proposed merger of the Company with GRI Bio, Inc. ("GRI Bio").  Under the merger agreement, Vallon will acquire 100% of the outstanding equity interests of GRI Bio, by means of reverse triangular merger of a wholly owned subsidiary of Vallon with and into GRI Bio, with GRI Bio surviving as a wholly owned subsidiary of Vallon.  Upon completion of the transaction, Vallon shareholders are expected to only own approximately 17% of the combined company, while GRI Bio shareholders are expected to own approximately 83%.